Sanofi: Information concerning the total number of voting rights and shares - October 2026
Sanofi (SNY) Is Planning for a Patent Loss, Here’s Where Bulls Still See Opportunity
Sanofi ADR (NASDAQ:SNY): Dividend Quality Just Clears the Bar
Sanofi (ENXTPA:SAN) Could Be 16% Overvalued After Strong Q3 Results And Higher 2026 Guidance
Sanofi Stock And Why Earnings Guidance Raised Matters For Shareholders
Sanofi (ENXTPA:SAN) Stock Looks Discounted Despite Its 20% Monthly Run
Sanofi 2026 Q3 - Results - Earnings Call Presentation
Sanofi (SNY) Q3 2026 Earnings Call Transcript
Sanofi (ENXTPA:SAN) Stock Can Q3 Earnings Sustain Its Revenue Strength
Sanofi (SAN:CA) Q3 2026 Earnings Call Transcript
Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It
Sanofi CEO Belen Garijo Says Beyond 2030, Expect Total Revenues To Be Impacted Only Moderately By Dupixent's Loss Of Exclusivity
Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance
Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded
Sanofi Q3 Adj. EPS $2.04 Beats $1.63 Estimate, Sales $16.623B Beat $15.230B Estimate
Sanofi: An Alluring And Balanced Mix Of Yield And Growth
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Sanofi and ScionxBio partner on mRNA therapies
Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.